[A22-61] Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2022
Project no.:
A22-61
Commission:
Commission awarded on 25.05.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD1 or PD-L1 inhibitor
- Patients for whom chemotherapy is suitable: hint of minor added benefit
- Patients for whom chemotherapy is unsuitable: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-107 | Enfortumab vedotin (urothelial carcinoma) – Addendum to Commission A22-61 | Commission completed |
| G22-37 | Enfortumab vedotin (urothelial cancer) – 2nd addendum to commission A22-61 | Commission completed |
| A24-98 | Enfortumab vedotin (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V | Commission work started |
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.
G-BA documents on this decision